Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Debt (2019 - 2025)

Vivos Therapeutics' Total Debt history spans 4 years, with the latest figure at $8.8 million for Q4 2025.

  • Quarterly results put Total Debt at $8.8 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $8.8 million (changed N/A YoY), and the annual figure for FY2025 was $8.8 million, changed.
  • Total Debt for Q4 2025 was $8.8 million at Vivos Therapeutics, up from $8.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $8.8 million in Q4 2025 to a low of $1.3 million in Q4 2021.